Welcome to our dedicated page for ESTABLISHMENT LABS HOLDINGS SEC filings (Ticker: ESTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ESTABLISHMENT LABS HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ESTABLISHMENT LABS HOLDINGS's regulatory disclosures and financial reporting.
Establishment Labs Holdings Inc. will hold its 2026 annual shareholder meeting virtually on May 22, 2026 at 1:00 pm Eastern Time. Shareholders will vote on electing six directors to one-year terms ending in 2027, an advisory “say‑on‑pay” approval of named executive officer compensation, and ratification of CBIZ CPAs P.C. as independent auditor for 2026.
The company reports 2025 revenue of $211.1 million, up 27.2% from 2024, with net loss narrowing to $51.1 million from $84.6 million and year‑end cash of $75.6 million. New CEO Filippo “Peter” Caldini’s pay mix emphasizes stock options, restricted stock units and an annual bonus tied to financial and strategic goals, reflecting a performance‑based compensation design.
ESTABLISHMENT LABS HOLDINGS INC. director and Chief Executive Officer Filippo Caldini reported equity compensation awards. He received stock options for 24,879 common shares at an exercise price of $76.23 per share, expiring on February 18, 2036, and a separate grant of 14,266 common shares.
According to the grant terms, one-fourth of both the stock units and the option shares vest on February 18, 2027, with additional one-fourth portions vesting on each one-year anniversary after that date, as long as he continues as a service provider. Following the share grant, he directly holds 49,511 common shares.
ESTABLISHMENT LABS HOLDINGS INC. director Edward J. Schutter exercised a stock option to acquire additional equity in the company. He exercised options covering 36,780 common shares at an exercise price of $4.11 per share via a cash exercise. Following the transaction, he directly owns 175,382 common shares, and the exercised option position has been fully converted into stock. The option had a multi-year vesting schedule, with half the shares vesting in 2016 and the remainder vesting in equal annual installments thereafter.
ESTABLISHMENT LABS HOLDINGS INC. director Leslie Gillin received an equity grant of common shares as part of regular board compensation. She acquired 297 common shares on the transaction date instead of a quarterly cash retainer, with the share amount based on the $56.78 closing price.
The shares were issued under the company’s 2018 Equity Incentive Plan and increase her direct holdings to 16,044 common shares. This is a routine, compensation-related award rather than an open-market purchase or sale.
Slotkin Bryan reported acquisition or exercise transactions in this Form 4 filing.
Establishment Labs Holdings Inc. director Bryan Slotkin received an automatic grant of 286 common shares valued at $56.78 per share. These shares were taken in lieu of his quarterly cash retainer under the company’s Outside Director Compensation Policy and issued from the 2018 Equity Incentive Plan.
Following this award, Slotkin directly holds 30,256 common shares. This is a routine, compensation-related equity grant rather than an open‑market share purchase.
LEWIN NICHOLAS SHERIDAN reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Nicholas Sheridan Lewin received a grant of 440 common shares, elected in lieu of a quarterly cash retainer under the company’s Outside Director Compensation Policy. The shares were issued under the 2018 Equity Incentive Plan at a value based on the closing price of $56.78 per share.
Following this compensation award, Lewin directly holds 1,077,315 common shares. An additional 19,090 common shares are held indirectly through his spouse, reflecting associated family holdings rather than an open-market trade.
SCHUTTER EDWARD J reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Edward J. Schutter received 330 common shares on March 31, 2026 as a share-based retainer. The shares were issued under the company’s 2018 Equity Incentive Plan instead of a quarterly cash retainer, based on the closing share price for the quarter’s last trading day.
After this grant, Schutter directly holds 138,602 common shares, so the award represents a small, routine addition to his existing stake rather than an open-market purchase or sale.
Custin Ann reported acquisition or exercise transactions in this Form 4 filing.
ESTABLISHMENT LABS HOLDINGS INC. director Custin Ann reported receiving a grant of 363 common shares. The shares were awarded in lieu of a quarterly cash retainer under the company’s Outside Director Compensation Policy, based on a closing price of $56.78 per share.
After this equity award issued pursuant to the 2018 Equity Incentive Plan, Custin Ann directly holds a total of 21,732 common shares.
Establishment Labs Holdings Inc. director Juan Jose Chacón Quirós reported an indirect open-market sale of 3,575 common shares at a weighted average price of $60.075 per share. The shares were sold by Sariel Group Ltd. under a pre-arranged Rule 10b5-1 trading plan.
After the sale, indirect holdings reported for Sariel Group Ltd. totaled 1,220,004 common shares, and Chacón Quirós also reported 45,193 common shares held directly. He disclaims beneficial ownership of shares held by Sariel Group Ltd. except to the extent of his pecuniary interest.
ESTABLISHMENT LABS HOLDINGS INC. director Juan Jose Chacon Quiros reported a mix of entity restructuring and open-market sales of Common Shares. A total of 179,240 shares moved from his direct holdings to Sariel Group Ltd. in an exempt transfer, leaving him with 45,193 shares held directly.
Through Sariel Group Ltd., an entity in which he is a shareholder with voting and dispositive power, 33,925 shares were sold in open-market transactions on March 23, 2026 at prices generally between $60.00 and $63.01 per share under a Rule 10b5-1 trading plan. Following these transactions, 1,225,292 shares are reported as held indirectly via Sariel Group Ltd.